Oral supplementation with Leu-Ile, a hydrophobic dipeptide, prevents the impairment of memory induced by amyloid beta in mice via restraining the hyperphosphorylation of extracellular signal-regulated kinase

Behavioural Brain Research

Volumn 210, Issue 2, 2010, Pages 184-190

  Alkam, Tursun ^a,b,c   Nitta, Atsumi ^a,e   Furukawa Hibi, Yoko ^a   Niwa, Minae ^a,c   Mizoguchi, Hiroyuku ^a,d   Yamada, Kiyofumi ^a,e   Nabeshima, Toshitaka ^a,c,e  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Department of Basic Medicine   (China)

^c MEIJO UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY   (Japan)

^e Japanese Drug Organization of Appropriate Use and Research   (Japan)

Author keywords

Amyloid beta (25 35); Extracellular signal regulated kinase; Inducible nitric oxide synthase; Novel object recognition memory; Protein nitration

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[25-35]; BRAIN DERIVED NEUROTROPHIC FACTOR; DIPEPTIDE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LEUCYLISOLEUCINE; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE FUNCTION; GENE OVEREXPRESSION; HIPPOCAMPUS; MALE; MEMORY DISORDER; MOUSE; NITRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOGNITION;

ADMINISTRATION, ORAL; AMINOACETONITRILE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EXPLORATORY BEHAVIOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; HIPPOCAMPUS; ISOLEUCINE; LEUCINE; MALE; MEMORY DISORDERS; MICE; MICE, INBRED ICR; NITRIC OXIDE SYNTHASE TYPE II; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RECOGNITION (PSYCHOLOGY); TIME FACTORS;

EID: 77952322580     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.02.028     Document Type: Article

References (72)

1. Abe K., Hisatomi R., Misawa M. Amyloid beta peptide specifically promotes phosphorylation and nuclear translocation of the extracellular signal-regulated kinase in cultured rat cortical astrocytes. J Pharmacol Sci 2003, 93:272-278.
2. Ajenjo N., Cañón E., Sánchez-Pérez I., Matallanas D., León J., Perona R., et al. Subcellular localization determines the protective effects of activated ERK2 against distinct apoptogenic stimuli in myeloid leukemia cells. J Biol Chem 2004, 279:32813-32823.
3. Alkam T., Nitta A., Mizoguchi H., Itoh A., Murai R., Nagai T., et al. The extensive nitration of neurofilament light chain in the hippocampus is associated with the cognitive impairment induced by amyloid beta in mice. J Pharmacol Exp Ther 2008, 327:137-147.
4. Alkam T., Nitta A., Mizoguchi H., Itoh A., Nabeshima T. A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Aβ25-35. Behav Brain Res 2007, 180:139-145.
5. Alkam T., Nitta A., Mizoguchi H., Saito K., Seshima M., Itoh A., et al. Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice. Behav Brain Res 2008, 189:100-106.
6. Anderton B. Free radicals on the mind. Hydrogen peroxide mediates amyloid beta protein toxicity. Hum Exp Toxicol 1994, 13:719.
7. Bastianetto S., Quirion R. Natural antioxidants and neurodegenerative diseases. Front Biosci 2004, 9:3447-3452.
8. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994, 77:817-827.
9. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 2001, 7:548-554.
10. Butterfield D.A., Kanski J. Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide 1-42. Peptides 2002, 23:1299-1309.
11. Butterfield D.A., Reed T.T., Perluigi M., De Marco C., Coccia R., Keller J.N., et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res 2007, 1148:243-248.
12. Choi J., Malakowsky C.A., Talent J.M., Conrad C.C., Carroll C.A., Weintraub S.T., et al. Anti-apoptotic proteins are oxidized by Abeta25-35 in Alzheimer's fibroblasts. Biochim Biophys Acta 2003, 1637:135-141.
13. Chong Y.H., Shin Y.J., Lee E.O., Kayed R., Glabe C.G., Tenner A.J. ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem 2006, 281:20315-20325.
14. Enomoto T., Osugi T., Satoh H., McIntosh T.K., Nabeshima T. Pre-Injury magnesium treatment prevents traumatic brain injury-induced hippocampal ERK activation, neuronal loss, and cognitive dysfunction in the radial-arm maze test. J Neurotrauma 2005, 22:783-792.
15. Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 1998, 31:47-59.
16. Greig N.H., Giacobini E., Lahiri D.K. Advances in Alzheimer therapy: development of innovative new strategies. Curr Alzheimer Res 2007, 4:336-339.
17. Grundman M., Grundman M., Delaney P. Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc 2002, 61:191-202.
18. Guidi I., Galimberti D., Lonati S., Novembrino C., Bamonti F., Tiriticco M., et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2006, 27:262-269.
19. Heikkila R., Cohen G. Further studies on the generation of hydrogen peroxide by 6-hydroxydopamine. Potentiation by ascorbic acid. Mol Pharmacol 1972, 8:241-248.
20. Hua L.L., Zhao M.L., Cosenza M., Kim M.O., Huang H., Tanowitz H.B., et al. Role of mitogen-activated protein kinases in inducible nitric oxide synthase and TNFalpha expression in human fetal astrocytes. J Neuroimmunol 2002, 126:180-189.
21. Huang X., Atwood C.S., Hartshorn M.A., Multhaup G., Goldstein L.E., Scarpa R.C., et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999, 38:7609-7616.
22. Kubo T., Nishimura S., Kumagae Y., Kaneko I. In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res 2002, 70:474-483.
23. Kulich S.M., Horbinski C., Patel M., Chu C.T. 6-Hydroxydopamine induces mitochondrial ERK activation. Free Radic Biol Med 2007, 43:372-383.
24. Kuperstein F., Yavin E. ERK activation and nuclear translocation in amyloid-beta peptide- and iron-stressed neuronal cell cultures. Eur J Neurosci 2002, 16:44-54.
25. Lee W.C., Choi C.H., Cha S.H., Oh H.L., Kim Y.K. Role of ERK in hydrogen peroxide-induced cell death of human glioma cells. Neurochem Res 2005, 30:263-270.
26. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001, 21:8370-8377.
27. Lovell M.A., Xie C., Xiong S., Markesbery W.R. Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. J Alzheimers Dis 2003, 5:229-239.
28. Luth H.J., Munch G., Arendt T. Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res 2002, 953:135-143.
29. Ma Q.L., Harris-White M.E., Ubeda O.J., Simmons M., Beech W., Lim G.P., et al. Evidence of Abeta- and transgene-dependent defects in ERK-CREB signaling in Alzheimer's models. J Neurochem 2007, 103:1594-1607.
30. Marlatt M.W., Lucassen P.J., Perry G., Smith M.A., Zhu X. Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies. J Alzheimers Dis 2008, 15:199-210.
31. Martínez A., Lahiri D.K., Giacobini E., Greig N.H. Advances in Alzheimer therapy: understanding pharmacological approaches to the disease. Curr Alzheimer Res 2009, 6:83-85.
32. Maurice T., Lockhart B.P., Privat A. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 1996, 706:181-193.
33. Medina M.G., Ledesma M.D., Domínguez J.E., Medina M., Zafra D., Alameda F., et al. Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation. EMBO J 2005, 24:1706-1716.
34. Milton N.G. Amyloid-beta binds catalase with high affinity and inhibits hydrogen peroxide breakdown. Biochem J 1999, 344:293-296.
35. Milton N.G. Role of hydrogen peroxide in the aetiology of Alzheimer's disease: implications for treatment. Drugs Aging 2004, 21:81-100.
36. Milligan S.A., Owens M.W., Grisham M.B. Differential regulation of extracellular signal-regulated kinase and nuclear factor-kappa B signal transduction pathways by hydrogen peroxide and tumor necrosis factor. Arch Biochem Biophys 1998, 352:255-262.
37. Nathan C., Calingasan N., Nezezon J., Ding A., Lucia M.S., La Perle K., et al. Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med 2005, 202:1163-1169.
38. Nelson P.T., Braak H., Markesbery W.R. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 2009, 68:1-14.
39. Nitta A., Nishioka H., Fukumitsu H., Furukawa Y., Sugiura H., Shen L., et al. Hydrophobic dipeptide Leu-Ile protects against neuronal death by inducing brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis. J Neurosci Res 2004, 78:250-258.
40. Niwa M., Nitta A., Yamada Y., Nakajima A., Saito K., Seishima M., et al. An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-alpha protects against methamphetamine-induced rewarding effects and sensitization. Biol Psychiatry 2007, 61:890-901.
41. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001, 60:759-767.
42. Ohno M., Frankland P.W., Chen A.P., Costa R.M., Silva A.J. Inducible, pharmacogenetic approaches to the study of learning and memory. Nat Neurosci 2001, 4:1238-1243.
43. Opar A. Mixed results for disease-modification strategies for Alzheimer's disease. Nat Rev Drug Discov 2008, 7:717-718.
44. Park J.S., Woo M.S., Kim S.Y., Kim W.K., Kim H.S. Repression of interferon-gamma-induced inducible nitric oxide synthase (iNOS) gene expression in microglia by sodium butyrate is mediated through specific inhibition of ERK signaling pathways. J Neuroimmunol 2005, 168:56-64.
45. Pei J.J., Braak H., An W.L., Winblad B., Cowburn R.F., Iqbal K., et al. Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res Mol Brain Res 2002, 109:45-55.
46. Perry G., Roder H., Nunomura A., Takeda A., Friedlich A.L., Zhu X., et al. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 1999, 10:2411-2415.
47. Pike C.J., Walencewicz-Wasserman A.J., Kosmoski J., Cribbs D.H., Glabe C.G., Cotman C.W. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 1995, 64:253-265.
48. Quinn J.F., Bussiere J.R., Hammond R.S., Montine T.J., Henson E., Jones R.E., et al. Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging 2007, 28:213-225.
49. Rapoport M., Ferreira A. PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons. J Neurochem 2000, 74:125-133.
50. Reiter C.D., Teng R.J., Beckman J.S. Superoxide reacts with nitric oxide to nitrate tyrosine at physiological pH via peroxynitrite. J Biol Chem 2000, 275:32460-32466.
51. Runyan J.D., Dash P.K. Intra-medial prefrontal administration of SCH-23390 attenuates ERK phosphorylation and long-term memory for trace fear conditioning in rats. Neurobiol Learn Mem 2004, 82:65-70.
52. Ryu J.K., McLarnon J.G. Minocycline or iNOS inhibition block 3-nitrotyrosine increases and blood-brain barrier leakiness in amyloid beta-peptide-injected rat hippocampus. Exp Neurol 2006, 198:552-557.
53. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997, 336:1216-1222.
54. Schubert D., Behl C., Lesley R., Brack A., Dargusch R., Sagara Y., et al. Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci USA 1995, 92:1989-1993.
55. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997, 17:2653-2657.
56. Tabner B.J., El-Agnaf O.M., Turnbull S., German M.J., Paleologou K.E., Hayashi Y., et al. Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia. J Biol Chem 2005, 280:35789-35792.
57. Thiels E., Klann E. Extracellular signal-regulated kinase, synaptic plasticity, and memory. Rev Neurosci 2001, 12:327-345.
58. Tran M.H., Yamada K., Olariu A., Mizuno M., Ren X.H., Nabeshima T. Amyloid beta-peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors. FASEB J 2001, 15:1407-1409.
59. Trojanowski J.Q., Mawal-Dewan M., Schmidt M.L., Martin J., Lee V.M. Localization of the mitogen activated protein kinase ERK2 in Alzheimer's disease neurofibrillary tangles and senile plaque neurites. Brain Res 1993, 618:333-337.
60. Valjent E., Caboche J., Vanhoutte P. Mitogen-activated protein kinase/extracellular signal-regulated kinase induced gene regulation in brain: a molecular substrate for learning and memory?. Mol Neurobiol 2001, 23:83-99.
61. Villard V., Espallergues J., Keller E., Alkam T., Nitta A., Yamada K., et al. Antiamnesic and neuroprotective effects of the aminotetrahydrofuran derivative ANAVEX1-41 against amyloid beta(25-35)-induced toxicity in mice. Neuropsychopharmacology 2009, 34:1552-1566.
62. Vodovotz Y., Lucia M.S., Flanders K.C., Chesler L., Xie Q.W., Smith T.W., et al. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J Exp Med 1996, 184:1425-1433.
63. Wang X., Wang H., Xu L., Rozanski D.J., Sugawara T., Chan P.H., et al. Significant neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with apoptosis. J Pharmacol Exp Ther 2003, 304:172-178.
64. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
65. Webster B., Hansen L., Adame A., Crews L., Torrance M., Thal L., et al. Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. J Neuropathol Exp Neurol 2006, 65:142-451.
66. Yamada K., Nabeshima T. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol Ther 2000, 88:93-113.
67. Yamada K., Tanaka T., Han D., Senzaki K., Kameyama T., Nabeshima T. Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. Eur J Neurosci 1999, 11:83-90.
68. Yankner B.A., Lu T. Amyloid beta-protein toxicity and the pathogenesis of Alzheimer disease. J Biol Chem 2009, 284:4755-4759.
69. Zandi P.P., Anthony J.C., Khachaturian A.S., Stone S.V., Gustafson D., Tschanz J.T., et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004, 61:82-88.
70. Zhang H.T., Zhao Y., Huang Y., Dorairaj N.R., Chandler L.J., O'Donnell J.M. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Neuropsychopharmacology 2004, 29:1432-1439.
71. Zhang Y., Brovkovych V., Brovkovych S., Tan F., Lee B.S., Sharma T., et al. Dynamic receptor-dependent activation of inducible nitric-oxide synthase by ERK-mediated phosphorylation of Ser745. J Biol Chem 2007, 282:32453-32461.
72. Zhuang S., Schnellmann R.G. A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther 2006, 319:991-997.